Kagan Griffin1, Ilona Csizmadi2, Lauren E Howard1,3, Gina-Maria Pomann3, William J Aronson4, Christopher J Kane5, Christopher L Amling6, Matthew R Cooperberg7, Martha K Terris8, Jennifer Beebe-Dimmer9, Stephen J Freedland10,11,12. 1. Urology Section, Department of Surgery, Veterans Affairs Medical Centers, Durham, NC, USA. 2. Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 3. Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA. 4. Department of Urology, University of California at Los Angeles Medical Center, Los Angeles, CA, USA. 5. Division of Urology, Department of Surgery, University of California at San Diego Medical Center, San Diego, CA, USA. 6. Division of Urology, Department of Surgery, Oregon Health & Science University, Portland, OR, USA. 7. Department of Urology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. 8. Urology Section, Division of Surgery, Veterans Affairs Medical Center and Division of Urologic Surgery, Department of Surgery, Medical College of Georgia, Augusta, GA, USA. 9. Department of Oncology, Wayne State University School of Medicine, Detroit, MI, USA. 10. Urology Section, Department of Surgery, Veterans Affairs Medical Centers, Durham, NC, USA. stephen.freedland@cshs.org. 11. Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA. stephen.freedland@cshs.org. 12. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. stephen.freedland@cshs.org.
Abstract
PURPOSE: We aimed to study the associations between androgen-deprivation therapy (ADT)-induced weight changes and prostate cancer (PC) progression and mortality in men who had undergone radical prostatectomy (RP). METHODS: Data from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort were used to study the associations between weight change approximately 1-year post-ADT initiation and metastases, castration-resistant prostate cancer (CRPC), all-cause mortality (ACM), and PC-specific mortality (PCSM) in 357 patients who had undergone RP between 1988 and 2014. We estimated hazard ratios (HR) and 95% confidence intervals (95% CI) using covariate-adjusted Cox regression models for associations between weight loss, and weight gains of 2.3 kg or more, and PC progression and mortality post-ADT. RESULTS: During a median (IQR) follow-up of 81 (46-119) months, 55 men were diagnosed with metastases, 61 with CRPC, 36 died of PC, and 122 died of any cause. In multivariable analysis, weight loss was associated with increases in risks of metastases (HR 3.13; 95% CI 1.40-6.97), PCSM (HR 4.73; 95% CI 1.59-14.0), and ACM (HR 2.16; 95% CI 1.25-3.74) compared with mild weight gains of ≤ 2.2. Results were slightly attenuated but remained statistically significant in analyses that accounted for competing risks of non-PC death. Estimates for the associations between weight gains of ≥ 2.3 kg and metastases (HR 1.58; 95% CI 0.73-3.42), CRPC (HR 1.33; 95% CI 0.66-2.66), and PCSM (HR 2.44; 95% CI 0.84-7.11) were elevated, but not statistically significant. CONCLUSIONS: Our results suggest that weight loss following ADT initiation in men who have undergone RP is a poor prognostic sign. If confirmed in future studies, testing ways to mitigate weight loss post-ADT may be warranted.
PURPOSE: We aimed to study the associations between androgen-deprivation therapy (ADT)-induced weight changes and prostate cancer (PC) progression and mortality in men who had undergone radical prostatectomy (RP). METHODS: Data from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort were used to study the associations between weight change approximately 1-year post-ADT initiation and metastases, castration-resistant prostate cancer (CRPC), all-cause mortality (ACM), and PC-specific mortality (PCSM) in 357 patients who had undergone RP between 1988 and 2014. We estimated hazard ratios (HR) and 95% confidence intervals (95% CI) using covariate-adjusted Cox regression models for associations between weight loss, and weight gains of 2.3 kg or more, and PC progression and mortality post-ADT. RESULTS: During a median (IQR) follow-up of 81 (46-119) months, 55 men were diagnosed with metastases, 61 with CRPC, 36 died of PC, and 122 died of any cause. In multivariable analysis, weight loss was associated with increases in risks of metastases (HR 3.13; 95% CI 1.40-6.97), PCSM (HR 4.73; 95% CI 1.59-14.0), and ACM (HR 2.16; 95% CI 1.25-3.74) compared with mild weight gains of ≤ 2.2. Results were slightly attenuated but remained statistically significant in analyses that accounted for competing risks of non-PC death. Estimates for the associations between weight gains of ≥ 2.3 kg and metastases (HR 1.58; 95% CI 0.73-3.42), CRPC (HR 1.33; 95% CI 0.66-2.66), and PCSM (HR 2.44; 95% CI 0.84-7.11) were elevated, but not statistically significant. CONCLUSIONS: Our results suggest that weight loss following ADT initiation in men who have undergone RP is a poor prognostic sign. If confirmed in future studies, testing ways to mitigate weight loss post-ADT may be warranted.
Authors: Carmen Rodriguez; Stephen J Freedland; Anusila Deka; Eric J Jacobs; Marjorie L McCullough; Alpa V Patel; Michael J Thun; Eugenia E Calle Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-12-19 Impact factor: 4.254
Authors: Howard S Kim; Daniel M Moreira; Matthew R Smith; Joseph C Presti; William J Aronson; Martha K Terris; Christopher J Kane; Christopher L Amling; Stephen J Freedland Journal: BJU Int Date: 2010-09-22 Impact factor: 5.588
Authors: Matthew R Smith; Joel S Finkelstein; Francis J McGovern; Anthony L Zietman; Mary Anne Fallon; David A Schoenfeld; Philip W Kantoff Journal: J Clin Endocrinol Metab Date: 2002-02 Impact factor: 5.958
Authors: Roanne J Segal; Robert D Reid; Kerry S Courneya; Shawn C Malone; Matthew B Parliament; Chris G Scott; Peter M Venner; H Arthur Quinney; Lee W Jones; Monika E Slovinec D'Angelo; George A Wells Journal: J Clin Oncol Date: 2003-05-01 Impact factor: 44.544
Authors: Daniel A Galvão; Nigel A Spry; Dennis R Taaffe; Robert U Newton; John Stanley; Tom Shannon; Chris Rowling; Richard Prince Journal: BJU Int Date: 2008-03-11 Impact factor: 5.588
Authors: Hendrik Isbarn; Laurent Boccon-Gibod; Peter R Carroll; Francesco Montorsi; Claude Schulman; Matthew R Smith; Cora N Sternberg; Urs E Studer Journal: Eur Urol Date: 2008-10-14 Impact factor: 20.096
Authors: Shabbir M H Alibhai; Minh Duong-Hua; Rinku Sutradhar; Neil E Fleshner; Padraig Warde; Angela M Cheung; Lawrence F Paszat Journal: J Clin Oncol Date: 2009-06-08 Impact factor: 44.544